At its July 2020 meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of eleven medicines:
- 3 new anticancer drugs
- 1 Janus kinase inhibitor for rheumatoid arthritis
- 1 antibody for sickle-cell anaemia
- 1 vaginal ring for HIV prevention
- 1 combination of active ingredients for post-operative pain
- 1 biosimilar bevacizumab
- generic drugs.
The EU Commission will then decide whether the respective medicines will be part of the pharmaceutical market in the EU.